Filter results by

Guidance and Policy (2891)
Guidance (847)
Policy and Strategy (1906)
Quality Indicators (134)
Prescribing and Technical Information (161)
Secondary Evidence (924)
Evidence Summaries (873)
Evidence Uncertainties (55)
Primary Research (336)
Practice Based Information (147)
Case Studies (147)
Medicines Current Awareness (306)
Implementation Support (1962)
Information for the Public (1394)
Patient Decision Aids (9)

Area of interest

Clinical (1233)
Public Health (128)

Drugs and Technologies (55)

Source

Department of Health (0)
Centre for Mental Health (0)
Renal Association (0)
NIHR Dissemination Centre (0)
Monitor (0)
National Institute for Health and Care Excellence - NICE (55)

Date

From

To

View filters

Share
Linked In
Twitter
Facebook
Email
More...

Results for all evidence | National Institute for Health and Care Excellence - NICE | Drugs and Technologies | Evidence Uncertainties 1 - 10 of 55 sorted by relevance / date

Click export CSV or RIS to download the entire page or use the checkboxes to select a subset of records to download

Warning, download options selected.

The operation that you have selected will move away from the current results page, your download options will not persist.

Please click "Confirm" if you are happy to lose these search results.

Certolizumab pegol for treating moderate to severe plaque psoriasis (TA574/1)

Remove: National Institute for Health and Care Excellence - NICE source - 01 April 2019

Recommendation ID TA574/1 Question What are the cost associated with best supportive care? Any explanatory notes(if applicable)

Remove: Evidence Uncertainties filter
Tildrakizumab for treating moderate to severe plaque psoriasis (TA575/1)

Remove: National Institute for Health and Care Excellence - NICE source - 01 April 2019

Recommendation ID TA575/1 Question What are the costs associated with best supportive care? Any explanatory notes(if applicable)

Remove: Evidence Uncertainties filter
Darvadstrocel for treating complex perianal fistulas in Crohn's disease (TA556/1)

Remove: National Institute for Health and Care Excellence - NICE source - 01 January 2019

Recommendation ID TA556/1 Question Further research is recommended to resolve the uncertainties about the long-term clinical effectiveness

Remove: Evidence Uncertainties filter
Darvadstrocel for treating complex perianal fistulas in Crohn's disease (TA556/2)

Remove: National Institute for Health and Care Excellence - NICE source - 01 January 2019

Recommendation ID TA556/2 Question The health-related quality-of-life evidence of patients with perianal fistulas is also lacking, therefore

Remove: Evidence Uncertainties filter
Cochlear implants for children and adults with severe to profound deafness (TA566/1)

Remove: National Institute for Health and Care Excellence - NICE source - 01 March 2019

Recommendation ID TA566/1 Question What is the benefit of bilateral cochlear implantation compared with unilateral cochlear implantation

Remove: Evidence Uncertainties filter
Adalimumab, etanercept and ustekinumab for treating plaque psoriasis in children and young people (TA455/1)

Remove: National Institute for Health and Care Excellence - NICE source - 01 July 2017

Recommendation ID TA455/1 Question Trials that evaluate utility values (using generic preference-based measures) in children and young people

Remove: Evidence Uncertainties filter
Holoclar for treating limbal stem cell deficiency after eye burns (TA467/2)

Remove: National Institute for Health and Care Excellence - NICE source - 01 August 2017

Recommendation ID TA467/2 Question NICE recommended that further research should be designed to generate robust evidence of the clinical-

Remove: Evidence Uncertainties filter
Holoclar for treating limbal stem cell deficiency after eye burns (TA467/1)

Remove: National Institute for Health and Care Excellence - NICE source - 01 August 2017

Recommendation ID TA467/1 Question NICE agreed that further research was needed because there is currently no clinical- or cost-effectiveness

Remove: Evidence Uncertainties filter
Pembrolizumab for adjuvant treatment of resected melanoma with high risk of recurrence (TA553/1)

Remove: National Institute for Health and Care Excellence - NICE source - 01 December 2018

Recommendation ID TA553/1 Question Proposals for further data collection in the Cancer Drugs Fund include:- recurrence-free survival- distant

Remove: Evidence Uncertainties filter
Cilostazol, naftidrofuryl oxalate, pentoxifylline and inositol nicotinate for the treatment of intermittent claudication in people with peripheral arterial disease (TA223/1)

Remove: National Institute for Health and Care Excellence - NICE source - 01 May 2011

Recommendation ID TA223/1 Question A trial comparing the long-term effectiveness (beyond 24 weeks) of cilostazol, naftidrofuryl oxalate

Remove: Evidence Uncertainties filter

1
2
3
4
5
6
Next